Welcome to "This Week in Health Care," where we highlight top sector stories in a fast-hitting style that lets you get back to your weekend. Let's get started.
Xarelto strikes back! In the multibillion-dollar battle to replace the maligned blood-thinner warfarin, Pfizer
Everyone falls back on the aging baby boomers as a reason to be bullish on health care for the long term. Other investors like to highlight international markets like China and India, where a large segment of the population is now wealthy enough to afford expensive Western medicine. And if we combined an aging population in a wealthy international market, what would we have? Japan. Big Pharma has noticed that Japan spends $100 billion on drugs annually and that almost a quarter of the population is over 65. Japan's own Takeda is the dominant player there, yet it controls only 6.5% of the market. Pfizer is No. 2, and it's employing increasingly aggressive sales strategies to get patients to request drugs by name. Approval times are swiftening, and companies like Novartis
And for your weekend reading assignment: Don't miss out on the Fool's take on The Biggest Investor Worry of the Election Season; how to play A Drug Market That's 366 Million Strong; and why in the big biotech space Buybacks That Are Better Than Dividends.
See you next week!
Fool contributor David Williamson owns shares of Pfizer and Johnson & Johnson, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, Novartis, and Pfizer and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.